𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of recombinant interferon-α2b (Laferon) on human neuroblastoma cells

✍ Scribed by V. V. Kucher; G. Kh. Matsuka; O. M. Rozhmanova; E. V. Dolgaya; L. N. Stelmakh; N. Kh. Pogorelaya


Publisher
Springer US
Year
2000
Tongue
English
Weight
170 KB
Volume
32
Category
Article
ISSN
0090-2977

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Growth inhibitory effect of recombinant
✍ W. K. Alfred Yung; Peter A. Steck; Peter J. Kelleher; Richard P. Moser; Michael 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 491 KB

Growth inhibitory activity of recombinant alpha and beta interferon on two human glioma cell lines, EFC-2 and KE cells, was determined by two different growth assays. Recombinant beta interferon showed a slight growth inhibitory effect on EFC-2 cells at day 3, and maximum inhibition was seen on day

in vitro effects of recombinant human in
✍ L. Zeng; A. Buard; L. Saint-Etienne; M. C. Jaurand; J. Bignon; I. Monnet; P. Bro 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 722 KB

Malignant mesothelioma is a tumor arising from serous surfaces and often related to asbestos exposure. Malignant mesothelioma is resistant to various forms of therapy. Radiotherapy, surgery or chemotherapy only slightly improve prognosis. IFN-y produces complete or partial responses in stage-I patie

Genetic engineering of α2,6-sialyltransf
✍ Lucia Monaco; Annie Marc; Alex Eon-Duval; Giulia Acerbis; Gianfranco Distefano; 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 655 KB

The CHO cell line has achieved considerable commercial importance as a vehicle for the production of human therapeutic proteins, but is known to lack a functional copy of the gene coding for α2,6-sialyltransferase (EC 2.4.99.1). The cDNA for rat α2,6-ST was expressed in a recombinant CHO cell line m

Recombinant human leukocyte interferon-α
✍ S. Iacobelli; G. Scambia; C. Natoli; P. Benedetti Panici; G. Baiocchi; L. Perron 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 322 KB

We have previously reported the production of a new monoclonal antibody (MAb) (SP-2) recognizing a 90-kDa tumorassociated antigen, termed 9OK. which is increased in the serum of many cancer patients. Treatment of CG5 human breast cancer cells with recombinant interferon-a 2b (rlFN-a 2b) can increase